OIPE IAP82 SEP 21 2006 PATENT & TRADEMARK OFFICE

PTO/SB/08A & PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/24/2001 W&K Substitute for Form PTO-SB/08A, which is a US PTO Substitute for form 1449A/PTO and 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	10/677,074
Filing Date	October 1, 2003
First Named Inventor	Banan
Art Unit	1647
Examiner Name	
Attorney Docket Number	LOR133.1 (9720/90735)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number - Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	D1	6,964,769	11-15-2005	Sebbel et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	D2	WO 2005/055957-A1	06-23-2005	Birkett et al.		

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	D3	Lebray et al, Immunomodulatory drugs and therapeutic vaccine in chronic hepatitis B infection, *J. of Hepatology*, 2003, **39**:S151-159	
	D4	Nardin et al., Phase I Testing of a Malaria Vaccine Compound of Hepatits B Virus Core Particles Expressing *Plasmodium falciparum* Circumsporozoite Epitopes, *Infection and Immunity*, Vol. 72, No. 11, pp. 6519-27	
	D5	Oliveira et al, Safety and Enhanced Immunogenicity of a Hepatitis B Core Particle *Plasmodium falciparum* Malaria Vaccine Formulated in Adjuvant Montanide ISA 720 in a Phase I Trial, *Infection and Immunity*, June 2005, Vol. 73, No. 6, pp. 3587-97	
	D6	PCT/US04/05047 International Search Report, mailed July 17, 2006	

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.